These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
180 related articles for article (PubMed ID: 36479686)
41. Comparison of efficacy and safety between febuxostat and allopurinol in early post-renal transplant recipients with new onset of hyperuricemia. Shen X; Li J; Fu Q; Liu L; Gao X; Chen X; Chen P; Wang C J Clin Pharm Ther; 2019 Apr; 44(2):318-326. PubMed ID: 30582178 [TBL] [Abstract][Full Text] [Related]
43. Efficacy and tolerability of febuxostat in hyperuricemic patients with or without gout: a systematic review and meta-analysis. Ye P; Yang S; Zhang W; Lv Q; Cheng Q; Mei M; Luo T; Liu L; Chen S; Li Q Clin Ther; 2013 Feb; 35(2):180-9. PubMed ID: 23332451 [TBL] [Abstract][Full Text] [Related]
44. African American patients with gout: efficacy and safety of febuxostat vs allopurinol. Wells AF; MacDonald PA; Chefo S; Jackson RL BMC Musculoskelet Disord; 2012 Feb; 13():15. PubMed ID: 22316106 [TBL] [Abstract][Full Text] [Related]
45. An allopurinol-controlled, multicenter, randomized, open-label, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 2 exploratory clinical study. Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S44-9. PubMed ID: 21654269 [TBL] [Abstract][Full Text] [Related]
46. Low-dose febuxostat exhibits a superior renal-protective effect and non-inferior safety profile compared to allopurinol in chronic kidney disease patients complicated with hyperuricemia: A double-centre, randomized, controlled study. Yang N; Cao B J Clin Pharm Ther; 2022 Dec; 47(12):2214-2222. PubMed ID: 36403976 [TBL] [Abstract][Full Text] [Related]
47. The Association of Febuxostat Compared With Allopurinol on Blood Pressure and Major Adverse Cardiac Events Among Adult Patients With Hyperuricemia: A Meta-analysis. Barrientos-Regala M; Macabeo RA; Ramirez-Ragasa R; Pestaño NS; Punzalan FER; Tumanan-Mendoza B; Castillo RR J Cardiovasc Pharmacol; 2020 Oct; 76(4):461-471. PubMed ID: 32675751 [TBL] [Abstract][Full Text] [Related]
48. Febuxostat for the chronic management of hyperuricemia in patients with gout. Chinchilla SP; Urionaguena I; Perez-Ruiz F Expert Rev Clin Pharmacol; 2016; 9(5):665-73. PubMed ID: 26942273 [TBL] [Abstract][Full Text] [Related]
49. Cardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular comorbidities. White WB; Chohan S; Dabholkar A; Hunt B; Jackson R Am Heart J; 2012 Jul; 164(1):14-20. PubMed ID: 22795277 [TBL] [Abstract][Full Text] [Related]
50. Gout lessons from 2018: CARES, a direct comparison of febuxostat vs allopurinol, and CANTOS, IL1 blocker for cardiovascular risk minimisation. Jansen TLTA; Janssen M Clin Rheumatol; 2019 Jan; 38(1):263-265. PubMed ID: 30542798 [TBL] [Abstract][Full Text] [Related]
51. Comparative effectiveness of allopurinol versus febuxostat for preventing incident renal disease in older adults: an analysis of Medicare claims data. Singh JA; Cleveland JD Ann Rheum Dis; 2017 Oct; 76(10):1669-1678. PubMed ID: 28584186 [TBL] [Abstract][Full Text] [Related]
52. Response to: 'Correspondence to "Hypersensitivity reactions with allopurinol and febuxostat: a study using the Medicare claims data' by Ma Singh JA Ann Rheum Dis; 2022 Jun; 81(6):e108. PubMed ID: 32561599 [No Abstract] [Full Text] [Related]
53. Cost-Effectiveness Analysis of Lesinurad/Allopurinol Versus Febuxostat for the Management of Gout/Hyperuricemia in Italy. Ruggeri M; Basile M; Drago C; Rolli FR; Cicchetti A Pharmacoeconomics; 2018 May; 36(5):625-636. PubMed ID: 29557073 [TBL] [Abstract][Full Text] [Related]
54. Design and Rationale for the Veterans Affairs "Cooperative Study Program 594 Comparative Effectiveness in Gout: Allopurinol vs. Febuxostat" Trial. Timilsina S; Brittan K; O'Dell JR; Brophy M; Davis-Karim A; Henrie AM; Neogi T; Newcomb J; Palevsky PM; Pillinger MH; Pittman D; Taylor TH; Wu H; Mikuls TR Contemp Clin Trials; 2018 May; 68():102-108. PubMed ID: 29597007 [TBL] [Abstract][Full Text] [Related]
55. Diabetes and gout: efficacy and safety of febuxostat and allopurinol. Becker MA; MacDonald PA; Hunt BJ; Jackson RL Diabetes Obes Metab; 2013 Nov; 15(11):1049-55. PubMed ID: 23683134 [TBL] [Abstract][Full Text] [Related]
56. Efficacy and safety of febuxostat for prevention of tumor lysis syndrome in patients with malignant tumors receiving chemotherapy: a phase III, randomized, multi-center trial comparing febuxostat and allopurinol. Tamura K; Kawai Y; Kiguchi T; Okamoto M; Kaneko M; Maemondo M; Gemba K; Fujimaki K; Kirito K; Goto T; Fujisaki T; Takeda K; Nakajima A; Ueda T Int J Clin Oncol; 2016 Oct; 21(5):996-1003. PubMed ID: 27017611 [TBL] [Abstract][Full Text] [Related]
57. Safety and efficacy of oral febuxostat for treatment of HLA-B*5801-negative gout: a randomized, open-label, multicentre, allopurinol-controlled study. Yu KH; Lai JH; Hsu PN; Chen DY; Chen CJ; Lin HY Scand J Rheumatol; 2016 Jul; 45(4):304-11. PubMed ID: 26771445 [TBL] [Abstract][Full Text] [Related]
58. Increased risk of cardiovascular events and death in the initial phase after discontinuation of febuxostat or allopurinol: another story of the CARES trial. Ghang BZ; Lee JS; Choi J; Kim J; Yoo B RMD Open; 2022 Jun; 8(2):. PubMed ID: 35732345 [TBL] [Abstract][Full Text] [Related]
59. Comparison of persistence rates between allopurinol and febuxostat as first-line urate-lowering therapy in patients with gout: an 8-year retrospective cohort study. Kim A; Kim Y; Kim GT; Ahn E; So MW; Lee SG Clin Rheumatol; 2020 Dec; 39(12):3769-3776. PubMed ID: 32458236 [TBL] [Abstract][Full Text] [Related]
60. The efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age. Jackson RL; Hunt B; MacDonald PA BMC Geriatr; 2012 Mar; 12():11. PubMed ID: 22436129 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]